A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Clinical trial NCT02513550 · COMPLETED

Trial details

NCT number: NCT02513550
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Plaque Psoriasis

Start date: 2015-08-01
Primary completion: 2016-11-01
Enrollment: 1257

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.